



CSL Limited
ABN: 99 051 588 348
655 Elizabeth Street
Melbourne
Victoria 3000 Australia
T +613 9389 1911
F +613 9389 1434
[CSL.com](https://www.csl.com)

ASX Announcement

For immediate release

3 April 2025

CSL RESPONDS TO PROPOSED U.S. TARIFFS

Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY)

CSL notes the announcement by the United States Administration on 2 April 2025 that it intends to impose reciprocal tariffs on imports from all countries.

At this stage pharmaceutical products are not subject to the reciprocal tariffs.

CSL is continuing to assess the broader impact of the tariffs and will monitor further announcements by the U.S. Government.

We look forward to working with U.S. administration to ensure American patients retain access to our lifesaving medicines.

Authorised for lodgement by:

Fiona Mead
Company Secretary

For further information, please contact:

Investors:

Chris Cooper
Head, Investor Relations
CSL Limited
P: +61 455 022 740
E: chris.cooper@csl.com.au

Media:

Brett Foley
Communications
CSL Limited
P: +61 461 464 708
E: brett.foley@csl.com.au